肝癌临床试验招募信息（全球在招）
这里汇总了全球正在招募患者的 肝癌（国际通用名 hepatocellular carcinoma）新药临床试验，包含试验分期、招募状态、开展国家和研究团队联系方式，全部以中文呈现。数据实时来自全球最大的临床试验注册库 ClinicalTrials.gov。本页同时覆盖肝细胞癌、原发性肝癌、HCC等说法。
正在招募的肝癌新药试验
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
不适用招募中美国NCT03894917Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy
II 期招募中South KoreaNCT07493668A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
不适用招募中美国澳大利亚NCT06887348The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine
IV 期招募中中国NCT07150624A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
I 期招募中美国中国Israel日本NCT06858813CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
I 期招募中中国NCT06560827A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk
IV 期招募中中国NCT06930573Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
IV 期招募中美国NCT07405086Exploratory Blood-Based Biomarkers in TACE-Treated Hepatocellular Carcinoma
不适用招募中SerbiaNCT07378709Improving the Use of Immunotherapy to Treat Liver Cancer
不适用招募中BelgiumNCT07623265Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
I 期 / II 期招募中美国日本Puerto Rico中国台湾NCT07227012The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities
II 期招募中中国NCT07381634
肝癌试验不在中国大陆，还能参加吗？
可以尝试四条现实路径：查找国内同类试验、申请同情用药与扩展准入、赴境外研究中心入组、直接写信给申办方申请在华开展。本站提供中英文对照的咨询信模板，患者和家属填写基本情况即可生成。
查看四条路径与写信模板